Zebra Capital Management LLC Supernus Pharmaceuticals, Inc. Transaction History

Zebra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$20.2 - $25.05 $372,609 - $462,072	-18,446 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $73,418 - $106,927	-4,296 Reduced 18.89%	18,446 $438,000
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $34,983 - $59,774	-2,421 Reduced 9.62%	22,742 $409,000
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $230,370 - $336,713	11,559 Added 84.97%	25,163 $597,000
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $107,126 - $140,354	4,206 Added 44.75%	13,604 $373,000
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $281,564 - $365,300	9,398 New	9,398 $311,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Zebra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Zebra Capital Management LLC with notifications on news.